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See related research by Schwarzer et al., http://www.ccforum.com/content/19/1/321Schwarzer et al. [1] showed discrepant postfilter ionized
calcium concentrations [iCa] when using different blood
gas analyzers (BGAs) and called for a change of the
Fresenius regional citrate anticoagulation (RCA) proto-
col to ensure patient safety. Of note, precision of the
BGAs was not tested.
In our opinion, the key message of their study is that
commercially available BGAs are not accurate when
measuring [iCa] outside the reference range and therefore
clinicians should avoid using multiple BGAs to guide
RCA in individual patients. However, there is no indica-
tion to change a RCA protocol which has been proven
safe and effective in >10 studies including >2000 patients
from different countries regardless of the BGA used [2–5].
Schwarzer et al. also raise concern about the potential
risk of life-threatening citrate intoxication. Whether
raised citrate levels are toxic or merely indicative of im-
paired cellular metabolism remains unclear, but excess
citrate can cause metabolic alkalosis. The Fresenius RCA
protocol and the technical specifications of the multifil-
trate machine both include safety mechanisms to detect
potential citrate accumulation early. The risk of citrate
toxicity is low (<3 %), even in high-risk patients with
liver failure [3, 5].
Given the proven advantages of RCA and the Kidney
Disease Improving Global Outcomes (KDIGO) recom-
mendation to use citrate as the first-line anticoagulant
during continuous renal replacement therapy, the accur-
acy of commercially available BGA devices should be
improved. In our opinion, there is no need to change a
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